resources archive

Scientific Publications
October 27th, 2023

Reconstructing disease dynamics for mechanistic insights and clinical benefit

Blog
August 22nd, 2023

Navigating Drug Development: CytoReason’s Disease Model Platform

Find out more about the Disease Model Platform by watching our new video
Scientific Publications
June 21st, 2023

Peripheral blood cellular dynamics of rheumatoid arthritis treatment informs about efficacy of response to disease modifying drugs

Media Coverage
February 1st, 2023

Making Clinical Trials Better for Everyone in 2023

Media Coverage
January 31st, 2023

Roundtable: What do you view as the most disruptive or transformational technology or development on the horizon?

Media Coverage
January 27th, 2023

Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances

Media Coverage
January 25th, 2023

Technology diffusion strategies for CIOs and the VC mindset

Media Coverage
January 24th, 2023

Sanofi extends cooperation with Israel’s CytoReason for bowel disease drug discovery

Media Coverage
January 24th, 2023

Follow the Money: University of Chicago Funds Biotech Accelerator, Breakthrough Tankless Inhaled Nitric Oxide Delivery System, More

Media Coverage
January 24th, 2023

Sanofi, CytoReason expand AI deal into IBD

Media Coverage
January 24th, 2023

CytoReason expands deal with Sanofi to look at IBD

Media Coverage
January 23rd, 2023

Sanofi and CytoReason Target IBD in Expanded Collaboration (Updated)

Media Coverage
January 23rd, 2023

Sanofi taps CytoReason’s AI models to target bowel disease

Media Coverage
January 23rd, 2023

CytoReason Licenses IBD Disease Model to Sanofi in Expanded Alliance

Media Coverage
January 23rd, 2023

Sanofi, CytoReason expanding collaboration to AI for inflammatory bowel disease targets

Media Coverage
January 23rd, 2023

CytoReason and Sanofi take collaboration into IBD

Media Coverage
January 23rd, 2023

Sanofi inks deal to expand AI use for drug discovery

Media Coverage
January 23rd, 2023

Sanofi extends deal with CytoReason

Media Coverage
January 23rd, 2023

Sanofi Extends Deal with CytoReason to License IBD Disease Modeling

Press Release Inner page
January 23rd, 2023

CytoReason to License Its IBD Disease Model to Sanofi in Expanded Multiyear, Multimillion Dollar Deal

Media Coverage
January 19th, 2023

2023 Predictions – the Good, the Bad, and the Ugly

Media Coverage
January 9th, 2023

Using Computational Disease Models and Synthetic Clinical Trials for Drug Research and Development with David Harel CytoReason

Media Coverage
January 5th, 2023

Executives Reunite at JPM as Biotech Kicks Off 2023

Press Release Inner page
November 29th, 2022

Poolbeg Pharma reaches R&D milestone as partner CytoReason completes AI influenza disease model

Media Coverage
December 1st, 2022

The Rise of Computational Biology in Biopharma

Media Coverage
October 7th, 2022

Pfizer Deepens Investment in CytoReason for Novel Drug Discovery and Development

Media Coverage
October 7th, 2022

Company of the Year 2022: Pfizer – Building on Covid-19

Media Coverage
September 28th, 2022

Follow the Money: NIH Funds Brain Mapping Network Initiative, Non-Invasive Skin Patch for Vaccine Delivery, More

Media Coverage
September 26th, 2022

CytoReason and Pfizer extend their alliance for AI delivery in drug discovery

Media Coverage
September 26th, 2022

Pfizer strengthens AI drug discovery collaboration with equity investment

Bring your data to life

Skip to content